Luis Cardentey, MD
Family Medicine · Fort Myers, FLNPI 1457640666
Payments from drug & device makers
Across 291 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$682
- Johnson & Johnson$662
- GSK$655
- Lilly USA, LLC$403
- Pfizer$336
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,120100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $1,116 |
| AstraZeneca | 43 | $682 |
| Johnson & Johnson | 21 | $662 |
| GSK | 38 | $655 |
| Lilly USA, LLC | 22 | $403 |
| Pfizer | 19 | $336 |
| Novartis | 17 | $330 |
| Novo Nordisk | 18 | $296 |
| Optinose US, Inc. | 2 | $257 |
| AbbVie | 10 | $188 |
| Esperion Therapeutics, Inc. | 11 | $174 |
| Exact Sciences | 5 | $111 |
| Boehringer Ingelheim | 7 | $109 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Antares Pharma, Inc. | 3 | $52 |
| Bayer | 2 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Convatec Inc. | 3 | $45 |
| Viiv Healthcare Company | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Merck | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $29 |
| Boston Scientific | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Orthogenrx Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,144 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 105 | $107,719 |
| OzempicSemaglutide | 69 | $101,187 |
| TrulicityDulaglutide | 68 | $87,297 |
| EliquisApixaban | 53 | $74,038 |
| OtezlaApremilast | 12 | $67,882 |
| MounjaroTirzepatide | 53 | $63,255 |
| JardianceEmpagliflozin | 40 | $54,968 |
| XareltoRivaroxaban | 26 | $38,330 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $33,478 |
| Repatha SureclickEvolocumab | 29 | $29,768 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $17,393 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,492 |
| EntrestoSacubitril/Valsartan | 15 | $15,359 |
| JanuviaSitagliptin Phosphate | 14 | $13,301 |
| QuviviqDaridorexant Hcl | 11 | $10,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $403 | $150,552121 claims |
| AstraZenecaFarxiga | $682 | $107,719105 claims |
| Novo NordiskOzempic | $296 | $101,18769 claims |
| PfizerEliquis | $336 | $74,03853 claims |
| AmgenOtezla | $1,116 | $67,88212 claims |
| Boehringer IngelheimJardiance | $109 | $54,96840 claims |
| Johnson & JohnsonXarelto | $662 | $38,33026 claims |
| GSKTrelegy Ellipta | $655 | $16,49220 claims |
| NovartisEntresto | $330 | $15,35915 claims |
| MerckJanuvia | $34 | $13,30114 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $54 | $10,79811 claims |
| AbbVieSynthroid | $188 | $2,11722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Myers
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.